Two distinct mechanisms of small molecule inhibition of LpxA acyltransferase essential for lipopolysaccharide biosynthesis
Han, W.; Ma, X.; Balibar, C. J.; Baxter Rath, C. M.; Benton, B.; Bermingham, A.; Casey, F.; Chi-Leon, B.; Cho, M.-K.; Frank, A. O.; Frommlet, A.; Ho, C.-M.; Lee, P. S.; Li, M.; Lingel, A.; Ma, S.; Merritt, H.; Ornelas, E.; de Pascale, G.; Prathapam, R.; Prosen, K. R.; Rasper, D.; Ruzin, A.; Sawyer, W.; Shaul, J.; Shen, X.; Shia, S.; Steffek, M.; Subramanian, S.; Vo, J.; Wang, F.; Wartchow, C.; Uehara, T.
Show abstract
The lipopolysaccharide biosynthesis pathway is considered an attractive drug target against the rising threat of multidrug-resistant Gram-negative bacteria. Here, we report two novel small-molecule inhibitors (compounds 1 and 2) of the acyltransferase LpxA, the first enzyme in the lipopolysaccharide biosynthesis pathway. We show genetically that the antibacterial activities of the compounds against efflux-deficient Escherichia coli are mediated by LpxA inhibition. Consistently, the compounds inhibited the LpxA enzymatic reaction in vitro. Intriguingly, using biochemical, biophysical, and structural characterization, we reveal two distinct mechanisms of LpxA inhibition; compound 1 is a substrate-competitive inhibitor targeting apo LpxA and compound 2 is an uncompetitive inhibitor targeting the LpxA-product complex. Compound 2 exhibited more favorable biological and physicochemical properties than compound 1, and was optimized using structural information to achieve improved antibacterial activity against wild type E. coli. These results show that LpxA is a promising antibacterial target and imply the advantages of targeting enzyme-product complexes in drug discovery.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Inhibition of Mycobacterium tuberculosis DosRST two-component regulatory system signaling by targeting response regulator DNA binding and sensor kinase heme 94%
- Biosynthesis of peptidic thiooxazole metallophores installed by multinuclear nonheme iron enzymes. 94%
- Discovery of inhibitors for bacterial Arr enzymes ADP-ribosylating and inactivating rifamycin antibiotics 93%
Similar papers in this journal
- Covalent targeting leads to the development of LIMK1 isoform-selective inhibitors 95%
- Development of the first low nanomolar Liver Receptor Homolog-1 agonist through structure-guided design 95%
- Discovery of two structurally distinct classes of inhibitors targeting the nuclease MUS81 and enhancing efficacy of chemotherapy in cancer cells 95%
Similar papers in this journal
- Discovery and biosynthesis of biffamycin A, a novel glycotetrapeptide antibiotic 96%
- Chemical validation of Mycobacterium tuberculosis phosphopantetheine adenylyltransferase using fragment linking and CRISPR interference 93%
- Structure-based Evolution of G protein-biased μ-opioid Receptor Agonists 93%
Similar papers in this journal
- Structure-aided development of small molecule inhibitors of ENPP1, the extracellular phosphodiesterase of the immunotransmitter cGAMP 95%
- Armeniaspirols inhibit the AAA+ proteases ClpXP and ClpYQ leading to cell division arrest in Gram-positive bacteria 94%
- Reprogramming Cbx8-Prc1 Function With A Positive Allosteric Modulator 93%
Similar papers in this journal
- Structural and dynamic studies uncover a distinct allosteric modulatory site at the mu-opioid receptor 95%
- Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease 94%
- An anti-virulence drug targeting the evolvability protein Mfd protects against infections with antimicrobial resistant ESKAPE pathogens 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.